Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. - Wikidata - awgldk - TriplyDB

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

http://www.wikidata.org/entity/Q35123154

about

Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data Chronic lymphocytic leukemia: a clinical review including Korean cohorts Current concepts in diagnosis and treatment of chronic lymphocytic leukemia Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab Management of elderly and unfit patients with chronic lymphocytic leukemia.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.Initial treatment of CLL: integrating biology and functional status.Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future.Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.Obinutuzumab for the treatment of indolent lymphoma Recent advances in therapy of chronic lymphocytic leukaemia.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.Spotlight on landmark oncology trials: the latest evidence and novel trial designs.Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.[Chronic lymphocytic leukemia : treatment concepts in transition].

P2860

Q26738934-39B72EB5-E650-496E-B7E3-988DB5E3966D Q26752467-C2E69BAA-C7CF-4EA2-9A7D-5773EA36FD52 Q26770471-C092F5F5-C929-40BE-BD3B-0BAEE5F43FAD Q26781163-A5D6C3D2-9EEC-49BB-B880-E4E6960C4FCA Q26783600-36EC56D7-CA4C-463E-AF89-37421EC035FB Q26801292-A4D86234-3024-4BA8-9B94-060764AEE485 Q30243914-AF98074E-429C-4BD6-A75E-F383CE06DC54 Q33880538-B0C7C6D2-4BB3-4FB2-87C4-34DED74DEEB3 Q34172063-9F4B300B-A67C-413D-BCF1-93315083581A Q34272532-E2B51920-D873-4A9E-B2BF-D6940D33066A Q34440110-52345EFE-4D32-48A4-97A5-734E59C460E8 Q34625543-B74E2524-718A-405E-9BC7-0AAA1DD6925B Q35110582-C01A6A92-D284-4904-A4C7-4D34B219E0D9 Q36219647-5ABF37CE-B4A4-47C2-98D1-85FE4B6A0271 Q36311212-05D4B6CE-9236-4FFC-B0F9-71436EB163CC Q36826893-1E7E1CA0-E768-4B0B-BF79-7EB11396C0EF Q38248969-3518D951-5199-418E-AF6C-60525D90329E Q38283828-4FF0BA2C-A4E5-489F-97C6-E431141F8629 Q38463695-8F71B715-7443-40E4-8865-E65082CB0C5D Q38489690-5BDA42F3-8955-4A46-A9E6-0BE251F08F35 Q38579008-F63830CB-FE0F-4F6E-9C09-B5AE0125004E Q38601727-759BB84D-04F0-43EC-912E-E072CC7906D4 Q38764077-629203FF-B38E-48DA-AE53-0944686FFB7F Q38818380-05A8B07E-8ED6-4075-9920-159DB16E99DE Q38862525-A2FB7877-9AB2-4FAE-9C41-374E10CE0E1C Q39200835-1AAB5FCB-03FD-4BD6-82DC-460B8D22C211 Q40736899-28E5F3ED-C994-4630-B09F-6FF25F0D0146 Q42343618-F74686A8-43E7-4023-8CC9-FB0EE83A5D08 Q46675870-6AB3FF93-51CE-4F25-AD3C-2F4552D79E52 Q47094907-64668D05-BFFB-4CDE-B7C7-4CE435ABEE89 Q47399742-451E4B27-5DE0-4698-BDDB-AAB37D48D11B Q48751476-B62ECB9E-7504-43DE-840A-41D71D2626B3 Q50118863-50E1BAC5-F7CC-44AF-BAF8-16B1D7B8DA82 Q55064971-7571C15E-1FF9-4EB1-9C49-38F20407360C

P2860

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

http://www.wikidata.org/entity/Q35123154

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Rituximab plus chlorambucil as ...... an open-label phase II study.

@ast

Rituximab plus chlorambucil as ...... an open-label phase II study.

@en

Rituximab plus chlorambucil as ...... an open-label phase II study.

@en-gb

type

label

Rituximab plus chlorambucil as ...... an open-label phase II study.

@ast

Rituximab plus chlorambucil as ...... an open-label phase II study.

@en

Rituximab plus chlorambucil as ...... an open-label phase II study.

@en-gb

prefLabel

Rituximab plus chlorambucil as ...... an open-label phase II study.

@ast

Rituximab plus chlorambucil as ...... an open-label phase II study.

@en

Rituximab plus chlorambucil as ...... an open-label phase II study.

@en-gb

P1433

Q35123154-3F195F01-0C53-460A-82D3-460D5EC20A38

P1476

Q35123154-C6C22167-DDE8-4D90-A46E-40AFDB275B5B

P2093

Q35123154-0735C67F-F3C2-40AB-84AB-D6BDB26F75D3

Q35123154-1AB35DCE-521D-4DA0-82BD-C3F3BD3E5B10

Q35123154-37012837-AA2C-46FD-AFD1-F43335DEBDF6

Q35123154-410C939F-8327-420A-B55D-D2E1CA36B90F

Q35123154-51148BF9-9091-4721-86C5-676FC4ED3E1D

Q35123154-71558803-5F5D-411A-AF2B-20138C2FD1E8

Q35123154-9C7A074F-F727-487C-95C3-E903F49311B0

Q35123154-ACB97AE7-9653-4E09-96AD-47D675E3470F

Q35123154-BC2A8C96-9D77-47C7-B017-B417E3054567

Q35123154-C5987EB4-E714-4228-B422-35C9EB22CE2F

P2860

Q35123154-23CB6422-5223-45AA-ADF0-72D50CA63F7C

Q35123154-5EACA33E-9C73-4B77-934F-00124F2B0047

Q35123154-6784BB5B-74D2-4792-8429-AA5E77D5DD7C

Q35123154-74A7CD51-0218-4EF0-A464-790E7341650A

Q35123154-834A6A1F-23B9-48BB-9264-127CF90CC877

Q35123154-8423E4D9-E0F9-4644-8214-A63B64C64368

Q35123154-9839C685-8172-49BB-B539-420BBCB932B1

Q35123154-B2FCE5F3-661A-4EF6-88C6-3EA965A83F6F

Q35123154-B3E06E19-2B15-4297-A145-C4434567E60C

Q35123154-B4DD6FAF-0E08-4188-BFE0-C3020C662781

P304

Q35123154-D54C2E68-7FCD-4116-B076-595A5D996984

P31

Q35123154-B455A40D-F4A3-46B7-B80B-99A66BA25D5F

P356

Q35123154-FF54A241-1BD9-43DE-A5C2-B18AFA7D5287

P407

Q35123154-F6A2F536-B950-41D2-83E1-62152744CBD6

P433

Q35123154-3A5418E6-8661-4289-A134-DB369BB51C68

P478

Q35123154-738092B0-F609-44B9-8AF3-B575A6D619A9

P50

Q35123154-266A5EA2-5B70-461D-B7C0-6D4BE646C564

Q35123154-438E2863-F31D-4995-834F-6A43358F6957

Q35123154-65E7611F-3711-44FA-89ED-AD19E94598AA

Q35123154-99B5715C-2539-45F1-82C0-A602C57735C5

P577

Q35123154-931F5AA6-0A10-4D5B-ACFD-10A8051AF02D

P698

Q35123154-23D3B1C2-7795-4D8A-AD43-1C9D278417D1

P921

Q35123154-4D2E548E-EB5E-438B-AD16-7E0526B07F05

Q35123154-62C53299-8995-4D90-A446-CCDD809A3A29

P932

Q35123154-31413590-4337-457D-ADD8-990824C29EEB

P356

JCO.2013.49.6547

P1433

Journal of Clinical Oncology

P1476

Rituximab plus chlorambucil as ...... an open-label phase II study.

@en

P2093

Abraham Varghese

http://www.w3.org/2001/XMLSchema#string

Amit Nathwani

http://www.w3.org/2001/XMLSchema#string

Andrew R Pettitt

http://www.w3.org/2001/XMLSchema#string

Christopher F E Pocock

http://www.w3.org/2001/XMLSchema#string

Daniel B Kennedy

http://www.w3.org/2001/XMLSchema#string

David G Oscier

http://www.w3.org/2001/XMLSchema#string

Donald Milligan

http://www.w3.org/2001/XMLSchema#string

George A Follows

http://www.w3.org/2001/XMLSchema#string

Hazem A Sayala

http://www.w3.org/2001/XMLSchema#string

John G Gribben

http://www.w3.org/2001/XMLSchema#string

P2860

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.

Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.

Cancer burden in the aged: an epidemiologic and demographic overview.

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.

P304

1236-1241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.49.6547

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Andy C Rawstron

Claire E. Dearden

P577

2014-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24638012

http://www.w3.org/2001/XMLSchema#string

P921

P932

4876343

http://www.w3.org/2001/XMLSchema#string